About: HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis
Creator	Hartung, Hans-Peter Berthele, Achim Cepok, Sabine Deisenhammer, Florian Grummel, Verena Hackermueller, Jörg Hemmer, Bernhard Hoffmann, Steve Lehmann-Horn, Klaus Wasmuth, Ralf Stadler, Peter
Source	Elsevier; Medline; PMC
abstract	The formation of antibodies to interferon-beta (IFN-β), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-β. In two independent continuous and binary-trait association studies, HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 (odds ratio: 5.15)—but not other HLA alleles—were strongly associated with the development of binding and neutralizing antibodies to IFN-β. The associated HLA-DRB1(∗)04 alleles differ from nonassociated HLA-DRB1(∗)04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1(∗)0401 and (∗)0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-β. In summary, we identified genetic factors determining the immunogenicity of IFN-β, a protein-based disease-modifying agent for the treatment of MS.
has issue date	2008-08-01(xsd:dateTime)
bibo:doi	10.1016/j.ajhg.2008.07.006
bibo:pmid	18656179
has license	green-oa
sha1sum (hex)	28e61ea3889ed6d0d984b2012594ce1e7ec5fbaa
schema:url	https://doi.org/10.1016/j.ajhg.2008.07.006
resource representing a document's title	HLA-DRB1(∗)0401 and HLA-DRB1(∗)0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis
has PubMed Central identifier	PMC2495071
has PubMed identifier	18656179
schema:publication	The American Journal of Human Genetics
resource representing a document's body	covid:28e61ea3889ed6d0d984b2012594ce1e7ec5fbaa#body_text
is schema:about of	named entity 'neutralizing antibodies' named entity 'biological effects' named entity 'Antibodies' named entity 'DEVELOPMENT' named entity 'MULTIPLE SCLEROSIS' named entity 'SUMMARY' named entity 'HLA-DRB1' named entity 'ANTIBODIES' named entity 'PRESENTATION' named entity 'BINARY' named entity 'MODIFYING' named entity 'GENETIC FACTORS' named entity 'CLINICAL PRACTICE' named entity 'IS A' named entity 'STUDIES' named entity 'TRAIT' named entity 'FORMATION' named entity 'INTERFERON-BETA' named entity 'BREAK' named entity 'MS.' named entity 'MOLECULE' named entity 'PROTEIN ' covid:arg/28e61ea3889ed6d0d984b2012594ce1e7ec5fbaa named entity 'TYPING' named entity 'RATIO' named entity 'DISEASE' named entity 'PROBLEM' named entity 'PROMOTE' named entity 'HIGH-RESOLUTION' named entity 'TOLERANCE' named entity 'A PROTEIN' named entity 'HLA' named entity 'THERAPEUTIC' named entity 'PEPTIDE' named entity 'TREATMENT' named entity 'IDENTIFIED' named entity 'IFN' named entity 'ANTIBODIES' named entity 'SUBSTITUTION' named entity 'HLA CLASS I' named entity 'ARTICLE' named entity 'THERAPY' named entity 'ASSOCIATED WITH' named entity 'ASSOCIATION' named entity 'BUT' named entity 'ALPHA-HELIX' named entity 'IN POSITION' named entity 'BINDING' named entity 'INTERFERON-B' named entity 'NEUTRALIZING ANTIBODIES' named entity 'AGENT' named entity 'DEVELOPMENT' named entity 'HLA-DRB1' named entity 'ASSOCIATED' named entity 'CLASS II' named entity 'BIOLOGICAL' named entity 'DRUG' named entity 'VALINE' named entity 'DECREASING' named entity 'ASSOCIATED WITH' named entity 'PEPTIDE-BINDING' named entity 'EFFECTS' named entity 'BASED' named entity 'EPITOPE' named entity 'INDEPENDENT' named entity 'CONTINUOUS' named entity 'MULTIPLE SCLEROSIS' named entity 'THESE' named entity 'MOTIF' named entity 'ALLELES' named entity 'GLYCINE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software